The company has significantly boosted this progress of a novel solution for cardiac amyloidosis, utilizing the investigational drug. Preliminary trial data indicates potential outcomes for individuals affected with this debilitating condition. This emphasis highlights the company’s focus to treating significant medical demands in the heart diseas